KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Operating Leases (2019 - 2025)

Novartis Ag (NVS) has disclosed Operating Leases for 7 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 8.1% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, down 8.1% year-over-year, with the annual reading at $1.7 billion for FY2025, 8.1% down from the prior year.
  • Operating Leases hit $1.7 billion in Q4 2025 for Novartis Ag, down from $1.8 billion in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.9 billion in Q4 2021 to a low of $23.0 million in Q4 2022.
  • Historically, Operating Leases has averaged $1.1 billion across 5 years, with a median of $1.7 billion in 2025.
  • Biggest five-year swings in Operating Leases: tumbled 98.79% in 2022 and later soared 1134.93% in 2024.
  • Year by year, Operating Leases stood at $1.9 billion in 2021, then crashed by 98.79% to $23.0 million in 2022, then soared by 534.78% to $146.0 million in 2023, then skyrocketed by 1134.93% to $1.8 billion in 2024, then decreased by 8.1% to $1.7 billion in 2025.
  • Business Quant data shows Operating Leases for NVS at $1.7 billion in Q4 2025, $1.8 billion in Q4 2024, and $146.0 million in Q4 2023.